CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...